Growth hormone peptide blend

Tesamorelin + Ipamorelin

The Egrifta SV label gives tesamorelin's mean elimination half-life as 8 minutes; the app lists 0.4 hours for the blend, and no study of the two peptides together was identified.1

Emerging evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Tesamorelin + Ipamorelin after one dose: 50% at ~0.4 h, 25% at 0.8 h, 12.5% at 1.2 h.

Drawn from the half-life in the app's model, ~0.4 h. The model's figures

Tesamorelin + Ipamorelin is a pre-mixed blend of two growth hormone-axis peptides, which the app lists at 5 mg of tesamorelin and 5 mg of ipamorelin. Tesamorelin is a growth hormone-releasing factor analog, and the Egrifta SV label gives its indication as the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.1 Ipamorelin is described in a phase 2 trial report as a ghrelin-receptor agonist.2 A search of PubMed for "tesamorelin ipamorelin" on 16 November 2026 returned 7 records, all typed as reviews, and a ClinicalTrials.gov search for the same words returned 0 studies. Every study described below is of one peptide on its own, so no result below is a result for the blend. The app grades the evidence for the blend as emerging. The registry names Theratechnologies as lead sponsor of the tesamorelin phase 3 trial and Helsinn Therapeutics (U.S.), Inc as lead sponsor of the ipamorelin postoperative ileus trial.3,4

Tesamorelin

The Egrifta SV label states that in vitro "tesamorelin binds and stimulates human GRF receptors with similar potency as the endogenous GRF".1 The label describes the natural hormone as "a hypothalamic peptide that acts on the pituitary somatotroph cells to stimulate the synthesis and pulsatile release of endogenous growth hormone (GH)".1 It states that "Tesamorelin stimulates growth hormone secretion, and subsequently increases IGF-1 and IGFBP-3 levels".1 The same label reports that "No clinically significant changes in the levels of other pituitary hormones, including thyroid-stimulating hormone (TSH), luteinizing hormone (LH), adrenocorticotropic hormone (ACTH) and prolactin, were observed in patients receiving EGRIFTA in clinical trials."1

Ipamorelin

Raun and colleagues of Novo Nordisk, in the European Journal of Endocrinology in 1998, describe ipamorelin as "a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2)", from the Novo Nordisk Department of GH Biology.5 In the in vitro work on primary rat pituitary cells, the authors report that "ipamorelin, like GHRP-6, stimulates GH release via a GHRP-like receptor".5 In swine, "None of the GH secretagogues tested affected FSH, LH, PRL or TSH plasma levels", and "Administration of both GHRP-6 and GHRP-2 resulted in increased plasma levels of ACTH and cortisol", whereas ipamorelin "did not release ACTH or cortisol in levels significantly different from those observed following GHRH stimulation".5 These are animal results from a paper by authors at Novo Nordisk, and they are not findings in people.5 Johansen and colleagues, also of Novo Nordisk, gave ipamorelin subcutaneously three times daily for 15 days to adult female rats (Growth Hormone and IGF Research, 1999) and reported that it "dose-dependently increased LGR from 42 microm/day in the vehicle group to 44, 50, and 52 microm/day in the treatment groups", with no effect on "total IGF-I levels, IGFBPs, or serum markers of bone formation and resorption".6 The same paper reports a pronounced and dose-dependent effect on body weight gain in these rats, and a plasma GH response to a provocative intravenous dose that was marginally reduced after ipamorelin treatment.6

The blend

No study of how the two peptides behave when mixed in one vial was identified in PubMed or ClinicalTrials.gov on 16 November 2026.

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~0.4 h
Bioavailability
4%
Typical dose
300–600 mcg
Route
SubQ
Time to peak
~0.3 h

The second column of the table holds the app's own figures, shown beside what the sources report for each peptide alone.

Table 3.1Half-life and pharmacokinetics5 rows
ParameterApp's figureReported in the sources
Half-lifeAbout 0.4 h (24 minutes), for the blendTesamorelin: mean elimination half-life of 8 minutes in healthy subjects after a single 1.4 mg subcutaneous Egrifta SV dose. Ipamorelin: terminal half-life of 2 hours after 15-minute intravenous infusions in healthy men1,7
Bioavailability4%Tesamorelin: absolute subcutaneous bioavailability of less than 4% in healthy adult subjects, measured with a 2 mg dose of the earlier Egrifta formulation. Ipamorelin: no figure in the sources cited1
Time to peakAbout 0.3 hTesamorelin: median peak plasma concentration time (Tmax) of 0.15 h in healthy and HIV-infected subjects. Ipamorelin: growth hormone, not ipamorelin, peaked at 0.67 hours in healthy men1,7
Volume of distributionNot givenTesamorelin: 4.8 ± 1.9 L/kg after a single 1.4 mg Egrifta SV dose in healthy subjects; 200 L in a population model of 38 people. Ipamorelin: 0.22 L/kg at steady state1,8,7
ModelOne compartmentTesamorelin: an open one-compartment model with first and zero order absorption and linear elimination was reported to suit 38 HIV-infected patients and healthy subjects given 1 or 2 mg subcutaneously daily for 14 days8

The label reports that tesamorelin's "mean extent of absorption (AUC) was 34% higher in HIV-infected patients than healthy subjects", and the population model found that "Age, body size measures, race and health status were not related to tesamorelin pharmacokinetic parameters within the range of covariates studied".1,8 The label adds that "No formal metabolism studies have been performed in humans" and that "Pharmacokinetics of tesamorelin in patients with renal or hepatic impairment, in pediatric patients, or in elderly patients has not been established".1 The app's half-life, bioavailability and time-to-peak figures are single figures listed for the blend, and the tesamorelin label figures above are for tesamorelin alone, so they differ.

Level over 6 weeks

Interval between doses

Level, as a share of the peak after one 100 mg dose

As studied: once daily (Egrifta SV label, tesamorelin alone)1.

An illustration from a pharmacokinetic model using a half-life of 0.4 hours. It is not a measured level or a suggested dose.

4

Human studies

No study of the blend was identified, so the table lists studies of tesamorelin and of ipamorelin separately.

Table 4.1Human studies6 rows
Study and yearDesignPeopleDose and lengthMain result
Falutz and colleagues, New England Journal of Medicine 2007 (tesamorelin)9Randomised, placebo-controlled; registry names Theratechnologies as lead sponsor9,3412 patients with HIV (86% men) with abdominal fat accumulation9Tesamorelin 2 mg or placebo subcutaneously daily, 26 weeks9Visceral adipose tissue fell 15.2% with tesamorelin and rose 5.0% with placebo; IGF-I rose 81.0% against a 5.0% fall; no significant difference in adverse events, but more tesamorelin patients withdrew because of one; no significant differences in glycemic measures9
Falutz and colleagues, Journal of Clinical Endocrinology and Metabolism 2010 (pooled phase 3 trials)10Pooled analysis of two randomised placebo-controlled trials, 26 weeks plus a 26-week extension10806 ART-treated patients with HIV and excess abdominal fat10Tesamorelin 2 mg (n = 543) or placebo (n = 263) subcutaneously daily, 26 weeks10Visceral adipose tissue -24 against 2 cm2 (treatment effect -15.4%); no significant change in abdominal subcutaneous adipose tissue; IGF-I +108 against -7 ng/ml; no clinically meaningful glucose differences10
Egrifta SV label, Studies 1 and 2 (tesamorelin)1Two randomised, double-blind, placebo-controlled studies, 2:1, 26-week main phase1412 and 404 HIV-infected patients with lipodystrophy and excess abdominal fat12 mg of the earlier Egrifta formulation or placebo subcutaneously daily, 26 weeks1Mean treatment differences in percent change in visceral adipose tissue of -20 (95% CI -24 to -15) in Study 1 and -12 (-16 to -7) in Study 2; 26-week completion rates 80% and 74%1
Gobburu and colleagues, Pharmaceutical Research 1999 (ipamorelin)7Dose-escalation pharmacokinetic and pharmacodynamic trial7Eight healthy men at each of 5 dose levels715-minute intravenous infusions at 5 infusion rates, 4.21 to 140.45 nmol/kg7Terminal half-life of 2 hours; a single episode of GH release peaking at 0.67 hours; larger variability in the pharmacodynamic than the pharmacokinetic parameters7
Beck and colleagues, International Journal of Colorectal Disease 2014 (ipamorelin)2Multicenter, double-blind, placebo-controlled phase 2; registry names Helsinn as lead sponsor2,4117 adults enrolled, 114 analysed, having small or large bowel resection2Ipamorelin 0.03 mg/kg or placebo intravenously twice daily, postoperative day 1 to 7 or discharge2Median time to first tolerated meal 25.3 h against 32.6 h (p = 0.15); any treatment-emergent adverse event in 87.5% against 94.8%; no significant differences in key and secondary efficacy analyses2
Registered phase 2 trial NCT01280344 (ipamorelin)11Phase 2; Helsinn lead sponsor; status COMPLETED11320 enrolled11Three ipamorelin regimens of 0.03 or 0.06 mg/kg intravenously twice or three times daily against placebo11No publication of its results was identified among the 3 records returned by a search of PubMed for "ipamorelin postoperative ileus"11

Deeper analysis: tesamorelin Study 1 (Falutz and colleagues, 2007)

Falutz and colleagues reported the trial in the New England Journal of Medicine in 2007, and the registry entry NCT00123253 names Theratechnologies as lead sponsor and lists 412 participants.9,3 The registry's official title calls it "A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg Dose of TH9507".3 The primary end point was the percent change from baseline in visceral adipose tissue on computed tomography, and secondary end points included triglycerides, total to HDL cholesterol ratio, IGF-I and self-assessed body image.9 Visceral adipose tissue "decreased by 15.2% in the tesamorelin group and increased by 5.0% in the placebo group", and triglycerides "decreased by 50 mg per deciliter and increased by 9 mg per deciliter, respectively".9 On safety the authors write that "Adverse events did not differ significantly between the two study groups, but more patients in the tesamorelin group withdrew from the study because of an adverse event".9 The glucose result was null: "No significant differences were observed in glycemic measures".9 The authors conclude the effects "might be useful in HIV-infected patients who have treatment-associated central fat accumulation".9 The label's account of the two phase 3 studies lists exclusion of body mass index of 20 kg/m2 or less, type 1 and type 2 diabetes mellitus, previous treatment with insulin or oral hypoglycemic or insulin-sensitizing agents, history of malignancy and hypopituitarism, and an age range of 18 to 65 years.1 The PubMed record for the article gives no limitations section and no funding statement, and lists an affiliation only for the first author, at Montreal General Hospital, McGill University Health Centre, so the authors' ties to the sponsor are not stated there.9

Deeper analysis: tesamorelin pooled analysis (Falutz and colleagues, 2010)

Falutz and colleagues pooled the two phase 3 studies in the Journal of Clinical Endocrinology and Metabolism in 2010: 806 patients, 543 on tesamorelin 2 mg and 263 on placebo, followed by a 26-week extension in which patients initially on tesamorelin were re-randomised to tesamorelin 2 mg (n = 246) or placebo (n = 135) and patients on placebo were switched to tesamorelin (n = 197).10 The main outcome was the percent change in visceral adipose tissue by computed tomography at week 26, with a treatment effect of "-15.4%".10 Abdominal subcutaneous adipose tissue did not change significantly (-2 against 2 cm2; P = 0.08), and IGF-I rose by 108 against a fall of 7 ng/ml.10 The authors state that "Treatment with tesamorelin was generally well tolerated" and that "No clinically meaningful differences were observed between groups in glucose parameters at wk 26 and 52".10 The PubMed record for this article gives no limitations section, funding statement or sponsor ties for the authors beyond the first author's affiliation at Montreal General Hospital, McGill University Health Centre.10 The registry names Theratechnologies as lead sponsor of NCT00123253, which the label lists as Study 1 of its two phase 3 studies, and the PubMed record for the pooled analysis states no sponsor or funding.3,1,10

Deeper analysis: ipamorelin in postoperative ileus (Beck and colleagues, 2014)

Beck and colleagues, of the Ochsner Clinic Foundation in New Orleans and the Ipamorelin 201 Study Group, reported the trial in the International Journal of Colorectal Disease in 2014.2 The trial was a multicenter, double-blind, placebo-controlled phase 2 study in adults having small or large bowel resection, and the registry lists masking as quadruple with Helsinn Therapeutics (U.S.), Inc as lead sponsor.2,4 Ipamorelin 0.03 mg/kg or placebo was given by intravenous infusion twice daily from postoperative day 1 to 7 or hospital discharge, and the key efficacy end point was time from first dose to tolerance of a standardised solid meal.2 Of 117 patients enrolled, 114 formed the safety and modified intent-to-treat populations.2 Median time to first tolerated meal was 25.3 hours with ipamorelin and 32.6 hours with placebo (p = 0.15), and treatment-emergent adverse events occurred in 87.5% and 94.8%.2 The authors conclude that "There were no significant differences between ipamorelin and placebo in the key and secondary efficacy analyses" and that "Ipamorelin 0.03-mg/kg twice daily for up to 7 days was well tolerated".2 Their stated limitation is that "This proof of concept study was small and enrolled patients with a broad range of underlying conditions".2 The PubMed record reports no deaths or discontinuations by group and no funding statement, and the registry lists a Helsinn study director; ties of the authors to Helsinn are not stated in the record.2,4

5

Doses reported in studies and on labels

The app's typical dose for the blend is 300 to 600 mcg subcutaneously, and the rows below give the doses that sources report for each peptide alone.

Table 5.1Doses reported in studies and on labels8 rows
SourceCompound and routeDose reportedPopulation and length
The app's figureBlend, subcutaneous300–600 mcgNo study of the blend was identified
Egrifta SV label1Tesamorelin, subcutaneous into the abdomen1.4 mg once dailyHIV-infected adult patients with lipodystrophy and excess abdominal fat
Studies 1 and 2 in the label1Tesamorelin (1 mg/vial formulation), subcutaneous2 mg daily against placebo26 weeks, 412 and 404 patients
González-Sales and colleagues 20158Tesamorelin, subcutaneous1 or 2 mg daily14 days, 38 HIV-infected patients and healthy subjects
Gobburu and colleagues 19997Ipamorelin, intravenous infusion4.21 to 140.45 nmol/kg over 15 minutesEight healthy men per dose level
Beck and colleagues 20142Ipamorelin, intravenous0.03 mg/kg twice dailyPostoperative day 1 to 7 or discharge, bowel resection patients
Registered trial NCT0128034411Ipamorelin, intravenous0.03 mg/kg twice daily, 0.06 mg/kg twice daily, 0.06 mg/kg three times dailyAgainst matching placebo, 320 enrolled
Johansen and colleagues 1999 (adult female rats, not people)6Ipamorelin, subcutaneous18, 90 and 450 microg/day, injected three times daily15 days

The label's dose is for tesamorelin alone in the indicated population, and the app's range for the blend is a different figure from any dose in the table.

Tesamorelin (label)

The label reports that 740 HIV-infected patients with lipodystrophy and excess abdominal fat were treated with Egrifta in clinical trials, 543 of them in the initial 26-week placebo-controlled phase.1 The most common adverse reactions (over 5%) it lists are "Arthralgia, injection site erythema, injection site pruritus, pain in extremity, peripheral edema, and myalgia".1 Injection site reactions occurred in 25% of tesamorelin-treated and 14% of placebo-treated patients in the first 26 weeks.1 The label also reports hypersensitivity reactions in 4% of patients treated with Egrifta in clinical trials, including pruritus, erythema, flushing, urticaria and rash.1 On glucose, the label says the treatment "can result in glucose intolerance", and that the percentages with HbA1c of 6.5% or more up to Week 26 were 5% with tesamorelin and 1% with placebo, with a hazard odds ratio of 3.3 (CI 1.4, 9.6).1 On fluid retention, the label states it "may occur during EGRIFTA SV therapy" with edema, arthralgia and carpal tunnel syndrome "which are either transient or resolve with discontinuation of treatment".1 Anti-tesamorelin IgG antibodies were detected in 50% of patients who received the earlier formulation for 26 weeks and 47% at 52 weeks.1 The label contraindicates Egrifta SV in "Patients with active malignancy", in disruption of the hypothalamic-pituitary axis, and in pregnancy.1 It also states that "The effects of prolonged elevations in IGF-1 levels are unknown."1

Ipamorelin

In the Beck trial, treatment-emergent adverse events occurred in 87.5% of the ipamorelin group and 94.8% of the placebo group, and the authors describe 0.03 mg/kg twice daily for up to 7 days as "well tolerated".2 A 2026 narrative review notes "no long term safety data available" for ipamorelin.12

Class review

The same review lists adverse effects reported for the growth hormone-axis peptides it covers, not for these two specifically: "Reported adverse effects span endocrine and metabolic disturbances (including prolactin and cortisol elevations, appetite changes, and dysglycaemia), fluid retention syndromes, musculoskeletal symptoms (myalgia/arthralgia), and injection-site reactions".12 It also cites "the uncertainty surrounding product composition, dose, and stacking practices in unregulated supply chains".12

The app lists IGF-1, blood glucose and insulin as markers to monitor. The Egrifta SV label states "Monitor IGF-1 levels during EGRIFTA SV therapy" and "Evaluate glucose status prior to initiating EGRIFTA SV".1 Among patients who received Egrifta for 26 weeks, "47% had IGF-1 levels greater than 2 standard deviation scores (SDS)", and at 52 weeks 34% had an IGF-1 SDS above 2.1 In the 2007 trial, glycemic measures "included glucose and insulin levels", and none differed significantly between groups.9 A 2026 review of peptides in urology and sexual medicine states that "Growth hormone secretagogues reliably increase growth hormone and insulin-like growth factor 1 concentrations; however, evidence for improved sexual function, physical performance, or quality of life remains limited."13

8

Regulatory and anti-doping status

The Egrifta SV label gives 2010 as the initial US approval year for tesamorelin and states that it "is not indicated for weight loss management as it has a weight neutral effect".1 It also states that "EGRIFTA SV is not indicated for use in pediatric patients with open or closed epiphyses".1 A DailyMed search for "tesamorelin" on 16 November 2026 returned 2 labels, both Egrifta products from Theratechnologies, and a search for "ipamorelin" returned 0 labels. A 2026 structured narrative review in JBJS Reviews says that growth hormone axis secretagogues "(e.g., CJC-1295, ipamorelin, and tesamorelin) remain investigational, with uncertain safety profiles, product quality concerns, and widespread antidoping restrictions".14 The World Anti-Doping Agency 2026 Prohibited List places both peptides in section S2, which is headed "PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)".15 Under S2.2.4 the list names tesamorelin among growth hormone-releasing hormone analogues, and ipamorelin among growth hormone secretagogues and their mimetics.15 The list states that "All prohibited substances in this class are non-Specified Substances".15 No regulator document for a tesamorelin and ipamorelin blend was identified in the searches run.

9

Storage and handling

Sources in this part

  1. 1Theratechnologies, 2026

The Egrifta SV label states "Store EGRIFTA SV 2 mg vial at room temperature at 20°C to 25°C (68°F to 77°F)" and "Protect EGRIFTA SV from light by keeping in the original box until time of use".1 Those statements are for the tesamorelin product alone, and the sources cited give no storage statement for a tesamorelin and ipamorelin blend.1

No study of tesamorelin and ipamorelin given together was identified in PubMed or ClinicalTrials.gov on 16 November 2026, so how the blend is absorbed, cleared and tolerated is not reported. The sources cited report no ipamorelin bioavailability figure for people, so the app's single blend figure of 4% rests on the tesamorelin label figure.1 The controlled tesamorelin trials were in HIV-infected patients with lipodystrophy, and the label states that "There is no information on the use of EGRIFTA SV in patients greater than 65 years of age".1 Of the ipamorelin human trials identified, the one published efficacy trial was in postoperative ileus and reported no significant differences from placebo in its key and secondary efficacy analyses, and a second registered phase 2 trial in that condition has no results publication among the records identified.2,11 The 2026 review of growth hormone-axis peptides says of ipamorelin used with CJC-1295 that the practice "is largely driven by anecdotal rationale, and controlled clinical evidence supporting synergy or meaningful body-composition outcomes in healthy individuals remains limited", and it does not address this blend.12

What is the half-life of Tesamorelin + Ipamorelin?

The Egrifta SV label gives tesamorelin's mean elimination half-life as 8 minutes in healthy subjects, and the app lists 0.4 hours (24 minutes) for the blend.1 A trial of eight healthy men per dose level reported a terminal half-life of 2 hours for ipamorelin after 15-minute intravenous infusions.7 No half-life measured for the two peptides together was identified.

What is in Tesamorelin + Ipamorelin?

The app lists 5 mg of tesamorelin and 5 mg of ipamorelin. Tesamorelin is a growth hormone-releasing factor analog and ipamorelin is a pentapeptide growth hormone secretagogue.1,5

Has Tesamorelin + Ipamorelin been studied in people?

No study of tesamorelin and ipamorelin given together was identified in PubMed or ClinicalTrials.gov on 16 November 2026. Tesamorelin has phase 3 trial data in HIV-infected patients with lipodystrophy, and ipamorelin has a phase 2 trial in postoperative ileus.9,2

Is tesamorelin FDA-approved?

The Egrifta SV label gives 2010 as the initial US approval year.1 It is indicated for "the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy" and is "not indicated for weight loss management".1

Is ipamorelin FDA-approved?

A DailyMed search for "ipamorelin" on 16 November 2026 returned 0 labels. A 2026 review describes ipamorelin as one of the growth hormone axis secretagogues that "remain investigational".14

Is Tesamorelin + Ipamorelin banned by WADA?

The WADA 2026 Prohibited List names both tesamorelin and ipamorelin under S2.2.4, in a section headed "PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)".15

What is the bioavailability of Tesamorelin + Ipamorelin?

The Egrifta label gives tesamorelin's absolute subcutaneous bioavailability as less than 4% in healthy adult subjects, and the app lists 4% for the blend.1 The sources cited report no bioavailability figure for ipamorelin in people.

How quickly does tesamorelin reach its peak level?

The Egrifta label gives a median time to peak plasma tesamorelin concentration of 0.15 hours in healthy and HIV-infected subjects, and the app lists about 0.3 hours for the blend.1

Does ipamorelin raise cortisol?

In swine, ipamorelin "did not release ACTH or cortisol in levels significantly different from those observed following GHRH stimulation", while GHRP-6 and GHRP-2 raised them, in a 1998 paper that is not a study of people.5 A 2026 review lists cortisol elevations among reported adverse effects of growth hormone-axis peptides as a group.12

13

References

  1. Theratechnologies. Egrifta SV (tesamorelin) for injection. US prescribing information, DailyMed record version 9, 2026. DailyMed label
  2. Beck DE, et al. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis 2014. PMID 25331030
  3. ClinicalTrials.gov. NCT00123253: TH9507 in Patients With HIV-Associated Lipodystrophy. Sponsor: Theratechnologies. NCT00123253
  4. ClinicalTrials.gov. NCT00672074: Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus. Sponsor: Helsinn Therapeutics (U.S.), Inc. NCT00672074
  5. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998. PMID 9849822
  6. Johansen PB, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res 1999. PMID 10373343
  7. Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res 1999. PMID 10496658
  8. González-Sales M, et al. Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects. Clin Pharmacokinet 2015. PMID 25358450
  9. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007. PMID 18057338
  10. Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two phase 3 trials with safety extension data. J Clin Endocrinol Metab 2010. PMID 20554713
  11. ClinicalTrials.gov. NCT01280344: Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function. Sponsor: Helsinn Therapeutics (U.S.), Inc. NCT01280344
  12. Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol 2026. PMID 42395176
  13. Vasylieva V, et al. Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review. Sex Med Rev 2026. PMID 42862021
  14. Villegas Meza AD, et al. Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications. JBJS Rev 2026. PMID 42160466
  15. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list